The Drug Enforcement Administration (DEA) recently extended, for a fourth time, Covid-era telemedicine flexibilities allowing providers to prescribe Schedule II – V controlled substances without an in-person visit, through December 31, 2026. This extension comes as concerns mount over the rapid expansion of at-home ketamine therapy, delivered via telehealth companies to tens of thousands of patients with depression, and the potential for inadequate medical oversight.
Michael Alvear, a health author and founder of KetamineTherapyForDepression.org, a noncommercial patient-advocacy site, has been analyzing online patient experiences and warns that the current model has crossed a line “from innovation to abdication of care.” Alvear’s research began after he successfully used esketamine (Spravato) in a medically supervised clinic, but found extended maintenance treatments unaffordable. He turned to online communities to explore more accessible options.
What he found in Reddit forums like r/TherapeuticKetamine and r/KetamineTherapy was not a source of helpful answers, but a “digital triage unit run by patients,” according to Alvear. He analyzed six months of posts and comments, identifying recurring patterns of dosing confusion, side effect management, and questions about the normalcy of their experiences. “When the same clinically specific questions and complaints…surface again and again, that’s not proof, but It’s an early-warning signal,” Alvear wrote in his analysis.
Telehealth companies like Joyous and Mindbloom are leading this expansion. Joyous recently reported data on over 45,000 patients, while Mindbloom states it has facilitated nearly 600,000 at-home ketamine dosing sessions in 38 states since 2019. These figures demonstrate the scale of a largely unsupervised experiment in mental health treatment.
The contrast with Alvear’s experience with Spravato is stark. During his in-clinic treatments, he was continuously monitored with a pulse oximeter, had a nurse checking his vitals, and had a psychiatrist immediately available. In the telehealth model, “supervision” is often limited to a video monitor during the first session, with subsequent sessions conducted solo.
The risks associated with unsupervised ketamine use are becoming increasingly apparent. The American Journal of Psychiatry recently documented a case of a woman becoming unresponsive after swallowing a 1,200 milligram dose of ketamine, requiring emergency treatment for overdose. Her blood ketamine level reached concentrations comparable to general anesthesia. Mindbloom is currently facing a wrongful death suit alleging improper medical oversight contributed to a patient’s overdose.
The death of actor Matthew Perry, widely publicized, served as a warning about the dangers of unsupervised ketamine use. More than two years ago, the Food and Drug Administration (FDA) issued a public warning against medically unmonitored use of at-home oral ketamine.
Alvear’s Reddit analysis revealed a range of concerning patient-reported side effects, including chronic vomiting, severe anxiety, and persistent bladder pain. Patients were frequently crowdsourcing dosing protocols and attempting to self-diagnose and manage complications. One user wrote, “I’ve been throwing up almost every time I use oral ketamine troches. The nausea is unbearable.” Another expressed fear of permanent bladder damage, and a third reported blood in their urine.
Significant discrepancies in prescribed dosages were also identified. While FDA-approved Spravato has a strict maximum of 84 mg per session, patients reported at-home prescriptions ranging from 50 mg to 800 mg. Some patients described terrifying experiences at higher doses, including dissociative states and psychotic episodes. Conversely, others reported no benefit even at high doses.
Alvear emphasizes that these patients are not misusing ketamine, but rather following their prescribers’ instructions within a system that prioritizes access over safety. He argues that the debate over access should distinguish between access to medication and access to comprehensive healthcare. “Sending a powerful dissociative drug to a vulnerable patient’s mailbox without a consistent safety protocol or real-time monitoring isn’t health care. It’s negligence,” he stated.
Following his analysis, Alvear abandoned his plan to try oral ketamine. He expressed concern that many patients lack the research skills and medical literacy to independently assess the risks and benefits of this treatment.
